Literature DB >> 9494772

In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women.

W Kuhnz1, A Heuner, M Hümpel, W Seifert, K Michaelis.   

Abstract

Previous studies with postmenopausal women receiving oral doses of norethisterone-containing preparations have shown that a small fraction of the dose is converted metabolically to ethinyl estradiol and may be detected in the peripheral blood. To investigate the extent and the dose dependence of this conversion in more detail, we performed a study with 24 postmenopausal women who received single oral doses of 5 mg norethisterone as well as 5 and 10 mg norethisterone acetate with a washout phase of 2 weeks between each treatment. After each treatment, blood was collected at regular intervals and the concentrations of norethisterone and ethinyl estradiol were analyzed in the serum samples by a specific radioimmunoassay and by gas chromatography/mass spectrometry, respectively. Ethinyl estradiol was present in the serum samples of all women following treatment with norethisterone acetate and, except for four cases, also after treatment with norethisterone. The conversion ratio of norethisterone acetate to ethinyl estradiol was 0.7 +/- 0.2% and 1.0 +/- 0.4% at doses of 5 and 10 mg, respectively. This corresponded to an oral dose equivalent of about 6 micrograms ethinyl estradiol per milligram of norethisterone acetate. For norethisterone, a conversion ratio of 0.4 +/- 0.4% was found at a dose of 5 mg, which corresponded to an oral dose equivalent of about 4 micrograms ethinyl estradiol per milligram of norethisterone. Although it cannot be excluded that in individual cases, even higher doses of ethinyl estradiol may be produced by conversion, it is concluded that at therapeutic doses of the progestogens, the exposure to metabolically derived ethinyl estradiol is probably of little clinical significance not only in fertile women using oral contraceptive combination preparations containing norethisterone and ethinyl estradiol, but also in postmenopausal women who receive oral doses of estradiol for estrogen replacement. The estrogenic effects of metabolically derived ethinyl estradiol on the liver (eg. synthesis of transport proteins) are very likely more than compensated due to the androgenic activity of norethisterone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9494772     DOI: 10.1016/s0010-7824(97)00174-1

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

Review 1.  Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception.

Authors:  Frank Z Stanczyk
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

2.  Acute uterine bleeding unrelated to pregnancy: a Southern California Permanente Medical Group practice guideline.

Authors:  Malcolm G Munro
Journal:  Perm J       Date:  2013

Review 3.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

4.  Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform.

Authors:  Caitlin Lynch; Srilatha Sakamuru; Ruili Huang; Diana A Stavreva; Lyuba Varticovski; Gordon L Hager; Richard S Judson; Keith A Houck; Nicole C Kleinstreuer; Warren Casey; Richard S Paules; Anton Simeonov; Menghang Xia
Journal:  Toxicology       Date:  2017-05-04       Impact factor: 4.221

Review 5.  Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Authors:  Frank Z Stanczyk; Janet P Hapgood; Sharon Winer; Daniel R Mishell
Journal:  Endocr Rev       Date:  2012-12-13       Impact factor: 19.871

6.  Transactivation of progestin- and estrogen-responsive promoters by 19-nor progestins in African Green Monkey Kidney CV1 cells.

Authors:  A M Pasapera; R Gutiérrez-Sagal; R García-Becerra; A Ulloa-Aguirre; J F Savouret
Journal:  Endocrine       Date:  2001-12       Impact factor: 3.633

7.  Norethisterone Reduces Vaginal Bleeding Caused by Progesterone-Only Birth Control Pills.

Authors:  Naama Vilk Ayalon; Lior Segev; Abraham O Samson; Simcha Yagel; Sarah M Cohen; Tamar Green; Hila Hochler
Journal:  J Clin Med       Date:  2022-06-13       Impact factor: 4.964

Review 8.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

Review 9.  Uterine Fibroids and Progestogen Treatment: Lack of Evidence of Its Efficacy: A Review.

Authors:  Jacques Donnez
Journal:  J Clin Med       Date:  2020-12-05       Impact factor: 4.241

Review 10.  Progestogens in menopausal hormone therapy.

Authors:  Małgorzata Bińkowska; Jarosław Woroń
Journal:  Prz Menopauzalny       Date:  2015-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.